Hims & Hers Partners with Novo Nordisk for FDA-Approved GLP-1s, Resolves Lawsuit, and Shifts Weight Loss Strategy
HIMS sits 99% above its 52-week low of $13.74 on elevated volume (3.9× avg).
Summary
Hims & Hers Health announced a strategic collaboration with Novo Nordisk to offer FDA-approved GLP-1 weight-loss medications, including Ozempic and Wegovy, while significantly scaling back its compounded GLP-1 offerings and resolving a lawsuit with Novo Nordisk.
Key Events · M&A and Partnerships · HIMS
-
Strategic Collaboration with Novo Nordisk
Hims & Hers has partnered with Novo Nordisk to offer FDA-approved GLP-1 medications, formalizing a deal previously reported in news.
-
Expanded Access to Branded GLP-1s
The platform will now provide Ozempic® and Wegovy® injections and pills, expanding access to a broad assortment of FDA-approved treatments later this month.
-
Strategic Shift in Weight Loss Offerings
The company will no longer advertise compounded GLP-1 offerings and will limit their availability to clinically necessary cases, aligning with a focus on FDA-approved drugs.
-
Lawsuit Dismissal by Novo Nordisk
Novo Nordisk has dismissed its lawsuit against Hims & Hers without prejudice, removing a significant legal and reputational overhang.
Analysis · HIMS · Industrial Applications And Services
This 8-K signals a pivotal strategic shift for Hims & Hers in the rapidly evolving GLP-1 weight loss market. The collaboration with Novo Nordisk, a leader in GLP-1s, secures access to highly demanded FDA-approved medications like Ozempic and Wegovy, which is crucial for long-term growth and credibility. The company's decision to de-emphasize compounded GLP-1s and cease their advertising, while potentially impacting some existing offerings, aligns with increasing regulatory scrutiny and consumer preference for branded, approved treatments. Critically, the dismissal of Novo Nordisk's lawsuit removes a significant legal and reputational risk, allowing Hims & Hers to focus on expanding its legitimate GLP-1 offerings. This move positions the company more strongly in the competitive telehealth landscape for weight management.
At the time of this filing, HIMS was trading at $27.39 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.